argenx SE (ARGX) Stock AnalysisARGXargenx SE

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications. It operates in the Healthcare sector.

Argenx SE is a strong buy at the current price of $1,023.21, supported by a recent positive Phase 3 trial result for Vyvgart Hytrulo, which showed a 15.4-point improvement in patients with autoimmune myositis. The stock has a forward P/E of 37.17, indicating growth potential, and analysts have set a price target as high as $1,415, suggesting significant upside from the current price. The main risk is the recent 5-day change of -1.59%, indicating some short-term volatility.

5 analysts cover ARGX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 1,048.